Skip to main content

crb-701

Generic: SYS6002·Code: SYS6002

crb-701: 2 clinical trials tracked.

crb-701 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about crb-701, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

Clinical Trial Registry Records (2)

A Randomized, 2-Arm Study to Evaluate the Efficacy and Safety of CRB-701 Compared With Investigator's Choice of Capecitabine, Cetuximab, or Docetaxel in Participants With Recurrent or Metastatic Oropharyngeal Squamous Cell Carcinoma Previously Treated With Platinum-based Chemotherapy and a PD-(L)1 Inhibitor

NCT07768189Registry updated 2026-08-26·Phase 3
Not yet recruiting

Primary endpoint: Objective Response Rate (%)

InterventionalRandomizedsingle260 targetStarted 2026-09Completion 2029-0328 sites · Austria, United Kingdom, United StatesCorbus Pharmaceuticals Inc.

A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients With Advanced Solid Tumors

NCT06265727Registry updated 2026-01-08·Phase 1/Phase 2
Recruiting

Primary endpoint: Part A: To confirm the safety and tolerability and determine MTD and PADR for CRB-701

InterventionalRandomizedopen348 targetStarted 2024-04Completion 2027-0141 sites · France, Italy, Moldova, Romania…Corbus Pharmaceuticals Inc.